sanguina About Us

Our Mission

The healthcare landscape is changing and people are looking to take control of their health from anywhere and everywhere. We not only support that, but we want to be the ones who help make it happen.

Our Mission

The healthcare landscape is changing and people are looking to take control of their health from anywhere and everywhere. We not only support that, but we want to be the ones who help make it happen.

How it Started

Our CEO and founder Erika, and her business partner, Rob, are just two of more than 1.62 billion people worldwide who struggle with anemia, the most common blood disorder.

Their personal battles inspired them to develop affordable and accessible products for regular anemia screening, so people like them could be proactive about their health.

sanguina About Us

How It Started

Our CEO and founder Erika, and her business partner, Rob, are just two of more than 1.62 billion people worldwide who struggle with anemia, the most common blood disorder.

Their personal battles inspired them to develop affordable and accessible products for regular anemia screening, so people like them could be proactive about their health.

sanguina About Us
Group photos of the Sanguina team

How It Started

How It Started

Our CEO and founder Erika, and her business partner, Rob, are just two of more than 1.62 billion people worldwide who struggle with anemia, the most common blood disorder.

Their personal battles inspired them to develop affordable and accessible products for regular anemia screening, so people like them could be proactive about their health.

A Brief History of Sanguina

2011
2013
2014
2017
2019
2020
2021
2022

Then-Georgia Tech student Erika Tyburski partners with Dr. Wilbur Lam for a senior design project for instant anemia screening. It’s there she meets Rob Mannino.

In this year, Erika and Rob launch the first AnemoCheck test prototype, win second place at the Georgia Tech Inventure Prize contest, first at the Georgia Tech Ideas to Serve, and secure their first grant.

AnemoCheck is written about in The Journal of Clinical Investigation, and Sanguina officially becomes a company.

The Food and Drug Administration approves first generation AnemoCheck for clinical use.

First generation AnemoCheck/AnemoCheck Home technology is granted a utility/method patent in the U.S., Europe, and Japan.

Sanguina secures $2.3 million in seed funding.

AnemoCheck is launched in the iOS and Google Play app stores in the United States!

Exciting news coming soon!

We like our jobs.

How It's Going

We’re researchers, designers, doctors, writers, and everyday people who are paving a new path in the healthcare industry to put the power directly in your hands—literally.

See who we are!

sanguina About Us
The Sanguina team at work

How It's Going

We’re researchers, designers, doctors, writers, and everyday people who are paving a new path in the healthcare industry to put the power directly in your hands—literally.

See who we are!